Author + information
- Nasser M. Lakkis, MD⁎ ()
- ↵⁎Ben Taub General Hospital, Baylor College of Medicine, 1709 Dryden, Suite 09.42, MS:BCM 620, Houston, Texas 77030
We thank Dr. Heras for her letter regarding our recent paper (1). We agree that dabigatran was misclassified in the last paragraph as a direct factor Xa inhibitor. As indicated in her letter, dabigatran is an oral direct thrombin inhibitor. We plan to dedicate another review to the impact of renal dysfunction on the safety and efficacy of this drug.
- American College of Cardiology Foundation